3 of September's Worst Performers

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Outerwall Inc (NASDAQ:OUTR), and Meritor Inc (NYSE:MTOR) tend to struggle in September

Aug 27, 2015 at 1:39 PM
facebook twitter linkedin

August has been a volatile month for the broader equities markets, with the major indexes headed for steep month-to-date losses. Things may only deteriorate in September, which, according to Schaeffer's Senior Quantitative Analyst Rocky White, has historically has been the worst for the S&P 500 Index (SPX) over the past 50 years. While a number of stocks have been known to buck the bearish trend -- these three specifically -- drugmaker Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), kiosk concern Outerwall Inc (NASDAQ:OUTR), and auto parts specialist Meritor Inc (NYSE:MTOR) have turned in some of the worst performances.


Since 2007, ACHN has averaged a loss of 11.9% in September, and has been positive just one-quarter of the time. It's already been a dismal year for the stock, which has shed nearly two-fifths of its value to hover near $7.60 -- and more recently, has been stuck churning below its 320-day moving average since early June.


In spite of these technical troubles, option traders have been quick to initiate long calls over puts in recent months. ACHN's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 7.56 ranks higher than 64% of all similar readings taken in the past year. (With 21.1% of the equity's float sold short, though, some of these calls could be of the protective kind.)

The brokerage bunch, meanwhile, has taken a glass-half-full approach to ACHN, with five out of eight analysts maintaining a "strong buy" recommendation. What's more, the average 12-month price target of $14.86 stands at a steep 49% premium to current trading levels. Should Achillion Pharmaceuticals, Inc. continue to struggle, an unwinding of optimism among option traders and/or analysts could translate into a fresh round of selling pressure.

Over the past 10 years, OUTR has lost an average of 4.8% in September, and has been positive just one time -- adding 9.6% in 2006. More recently, the security has been struggling since topping out at a record high of $85.26 in late July, down 25% at $63.77.


Similar to ACHN, call players have been active in recent months. Specifically, OUTR's 50-day ISE/CBOE/PHLX call/put volume ratio of 1.44 sits just 6 percentage points from a 52-week peak. However, more than two-fifths of the security's float is sold short, so it's possible some of the recent call buying -- particularly at out-of-the-money strikes -- is a result of short sellers hedging against any upside.

Elsewhere on the Street, it's more of a mixed bag. For instance, 10 brokerage firms currently follow OUTR -- five of which maintain a "strong buy" recommendation, and five of which deem the stock a "hold" or worse. Meanwhile, the average 12-month price target of $79.71 represents expected upside of 21% to the stock's present perch. Although Outerwall Inc is following in the bullish footsteps of the broader equities market today, a resumed downtrend could prompt downgrades and/or price-target cuts.

Going back 10 Septembers, MTOR has averaged a monthly loss of 4.1%, and is positive just 30% of the time. In fact, last September, the shares plunged more than 20%. A repeat of history would just be more of the same for a stock that's given back 17.3% since notching a three-year peak of $15.65 in early January.


Unlike its fellow September laggards, sentiment toward MTOR is mostly skewed toward the skeptical side. Short interest, for example, surged 17.6% in the latest reporting period, and now accounts for a healthy 6.9% of the security's available float. This represents more than a week's worth of trading, at average daily levels.

Additionally, seven analysts maintain a lackluster "hold" recommendation toward MTOR, versus two "buy" or better ratings. However, the consensus 12-month price target of $15.57 stands 20% above Meritor Inc's current price of $12.94, leaving the door wide open for a round of downwardly revised price targets.

Here's the entire list of September's 25 worst-performing stocks. To take a look at three stocks that had an outstanding summer, and could continue to see more gains heading into fall, click here.



Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!